Hello, everyone, and welcome to the working week. We hope the weekend was relaxing. Now, of course, the routine of meetings and deadlines resume. This calls, of course, for a cup or two of stimulation. So please join us as we indulge. Meanwhile, here are a few tidbits to get you started. Have a great day and keep us in mind if you hear something interesting. See you later...
Dendreon Faces Investor Uprising Led By Small Shareholder (Xconomy)
Vivus Diet Pill Has Heart Benefits (Bloomberg News)
BASF Raises API And Excipient Prices 10 Percent (InPharma Technologist)
Antidepressants Linked To Narrowed Arteries In Older Men (Bloomberg News)
Glaxo Faces Talent War In Emerging Markets (Bloomberg News)
Cipla Seeks Voluntary License To Make Merck AIDS Drug (MoneyControl)
FDA Staff Backs Efficacy Of Optimer Antibiotic (Reuters)
Bangladesh Readies An API Manufacturing Park (BD News24)
Actelion Board Nominees Deny Sale Is Main Goal (Reuters)
Roche To Lead Israel Stem Cell Consortium (Globes)
EDITOR'S NOTE: Please check this post for updates through the morning.